Skip to main content
Clinical Trials/NCT06389708
NCT06389708
Not Yet Recruiting
N/A

Evaluation of VEXUS Score of Patients With Heart Failure in the Intensive Care Unit.

Inonu University0 sites100 target enrollmentMay 15, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Inonu University
Enrollment
100
Primary Endpoint
MORTALİTY
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Heart failure is a syndrome that progresses with symptoms and signs caused by cardiac dysfunction and results in a shortened life expectancy (1). Acute heart failure resulting in hospitalization is a significant cause of morbidity and mortality. With the increase in the severity of the disease and rapid advances in the treatment of heart failure, these patients are frequently hospitalized and monitored in intensive care. (2) Five years after diagnosis, mortality can be up to 67%. Additionally, it is known that patients with heart failure are hospitalized on average once a year after diagnosis. (3) In a multicenter study, it constituted 14% of 3000 cardiac patients admitted to intensive care units. Additionally, due to longer ICU stays, these patients accounted for 33% of total inpatient days. An increasing number of heart failure patients require intensive care due to respiratory failure, regardless of left ventricular ejection fraction. Heart failure accounts for approximately one-third of patient days in intensive care units, and this burden is increasing. This shows that attention should be paid to the quality of care for patients requiring critical care. (2) Multidisciplinary programs have been implemented to deal with the high prevalence. However, the optimal follow-up frequency is unknown. Therefore, some tools are needed to improve patient prognosis (3). Neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker whose values in both urine and plasma have been associated with acute kidney injury (AKI). Although NGAL is an early specific biomarker for AKI, it has not yet come into routine use, but is frequently used in clinical and experimental studies (4). Venous load ultrasonography score (VExUS) is a new systemic congestion scoring method based on inferior vena cava dilation and pulsed wave Doppler (PW-Doppler) morphology of the hepatic, portal and renal veins. It has been proposed as a score to assess systemic congestion.

Detailed Description

Patients will be randomized according to the sealed envelope method. While classical heart failure fluid management will be applied to patients in the conventional group, diuretic treatment will be given to the vexus group in a way that will reduce the vexus score, and the drugs and doses used in this treatment will be recorded. The development of acute renal failure in patients will be determined according to KDIGO criteria, but confirmation will be made with NGAL. Patients will be divided into two groups: those treated according to the VEXUS score and those treated simultaneously with VEXUS by a second experienced person (INTENSIVE CARE SPECIALIST) but treated conservatively. Patients' vital parameters, complete blood count, biochemistry, coagulation, arterial blood gas, procalcitonin, CRP, troponin, pro-BNP levels on Day 1 and Day 5 will be noted, and distensibility will be detected by USG on Days 1 and 5 among those with an IVC diameter \< 2 cm. or collapsibility index, and for those \> 2cm, VEXUS score will be calculated. In addition, EF, TAPSE, presence of pleural effusion or B-Line, renal resistive index, renal pulsatility index will be calculated.

Registry
clinicaltrials.gov
Start Date
May 15, 2024
End Date
January 15, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ayse Belin Ozer

Head of Intensive Care Unit

Inonu University

Eligibility Criteria

Inclusion Criteria

  • • Patients with a life expectancy of more than 24 hours

Exclusion Criteria

  • Poor abdominal echogenicity
  • age \< 18
  • postoperative patients,
  • intoxications,
  • life expectancy is less than 24 hours,
  • pregnancy,
  • intraperitoneal pressure \> 15 mm Hg,
  • obstructive renal failure or suspected,
  • presence of renal artery stenosis,
  • patients who have had liver and kidney transplants,

Outcomes

Primary Outcomes

MORTALİTY

Time Frame: in 28 days

28 day mortality

AKI

Time Frame: last day

Acute kidney injury rate

VEXUS

Time Frame: at the first day, at the last day

Venous excess ultrasound score

Similar Trials